Journal: International Journal of Molecular Sciences
Article Title: Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension
doi: 10.3390/ijms22179105
Figure Lengend Snippet: SERCA2a overexpression increases BMPR2 expression in hPAECs. ( A ). SERCA2a (far-red, white color) and BMPR2 (red color) expression was measured by co-immunostaining in hPAECs infected with a control adenovirus encoding β-Galactosidase (Ad.βGal) or SERCA2a (Ad.S2a). Nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. ( B ). BMPR2 mRNA levels were measured by RT-qPCR in hPAECs infected with Ad.S2a or Ad.βGal for 24 hr and were treated with a STAT3 inhibitor (STAT3i; 1 µM) for 48 h, n = 3. ( C ). Representative immunoblots of SERCA2a, BMPR2, phospho-SMAD1-5-9 (p-SMAD-1-5-9), phospho-STAT3 T705 (p-STAT3 T705 ), Total-SMAD1 (T-SMAD1), Total-STAT3 (T-STAT3), and GAPDH in hPAECs in the indicated conditions. ( D – F ). Bar graph represents the quantification of p-STAT3 T705 ( D ), BMPR2 ( E ), p-SMAD1-5-9 ( F ), and normalized to T-STAT3, GAPDH, and T-SMAD1, respectively, n = 3. ( G ). Proliferation levels were measured by BrdU assay in hPAECs overexpressing SERCA2a alone for 48 h and/or were treated with a potent STAT3 inhibitor (STAT3i, 1 µM) for 72 h in a media containing 0.1% or 5% FBS, n = 4. ( H ). SERCA2a mRNA (left) or protein (right) expression was analyzed by RT-qPCR (left) and Western blot (right) in hPAECs overexpressing either a non-silencing shRNA (shNS) or a specific shRNA against SERCA2a (shSERCA2a), n = 3. ( I ). Bar graph represents the quantification of BMPR2 normalized to GAPDH, n = 3. ( J ). BMPR2 mRNA levels were measured by RT-qPCR in hPAECs overexpressing shNS or shSERCA2a alone or in combination with STAT3i (48 h, 1 µM), n = 3. ( K ). STAT3 mRNA or protein expression was analyzed using RT-qPCR (left) and Western blot (right) in hPAECs overexpressing either a non-silencing siRNA (siNS) or a specific siRNA against STAT3 (siSTAT3), n = 3. ( L ). Bar graph represents the quantification of BMPR2 normalized to GAPDH, n = 3. ( M ). BMPR2 mRNA levels were measured by RT-qPCR in hPAECs overexpressing a control vector or SERCA2a alone or in combination with siSTAT3 for 72 h, n = 3. ( N ). Proliferation levels were measured by BrdU assay in hPAECs overexpressing SERCA2a alone and/or BMPR2. Cells were cultured in 0.1% or 5% FBS for 72 h, n = 4. ( O ). Proliferation levels were measured by BrdU assay in hPAECs overexpressing either shSERCA2a alone or with BMPR2. Cells were treated with either 0.1% or 5% FBS for 72 h, n = 4. Data are presented as mean ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001.
Article Snippet: Human pulmonary artery endothelial cells (hPAECs) were purchased from Lonza, Inc. (Allendale, NJ, USA). hPAECs were cultured in EBM-2 medium supplemented with 5% fetal bovine serum (FBS) supplemented with EGM-2 SingleQuots (Lonza). hPAECs were characterized by immunofluorescence with antibodies specific to vWF/Factor VIII and CD31 (PECAM).
Techniques: Over Expression, Expressing, Immunostaining, Infection, Quantitative RT-PCR, Western Blot, BrdU Staining, shRNA, Plasmid Preparation, Cell Culture